AirSculpt® Introduces alloClae™ Through Strategic Partnership with Tiger Aesthetics™
In an unprecedented move aimed at enhancing body contouring options for patients nationwide, AirSculpt®, a pioneer in minimally invasive body contouring, has entered a strategic partnership with Tiger Aesthetics™. This collaboration ushers in the debut of alloClae™, a novel off-the-shelf structural adipose tissue specifically designed for aesthetic procedures.
Slated for launch this August, alloClae™ represents AirSculpt's commitment to making innovative treatments more accessible across its network of practices. While the specifics of the locations for initial offerings remain under wraps, we can expect this exciting development to roll out to various AirSculpt locations by the end of 2026.
AlloClae™ stands out as an advantageous treatment option for individuals seeking natural-looking volume restoration without the need for a traditional fat transfer procedure. Many patients might face challenges, particularly if they do not possess sufficient fat for such procedures. This new treatment can be seamlessly integrated into existing treatment plans, allowing for enhancements in multiple areas like the hips, buttocks, and breasts, as well as smoothing out irregularities resulting from previous liposuction.
Yogi Jashnani, the Chief Executive Officer of AirSculpt, expressed the company's dedication to ongoing innovation, stating, "At AirSculpt, we are continually evaluating new technologies that complement our expertise. Our partnership with Tiger Aesthetics reflects our commitment to remaining at the forefront of body contouring innovation, allowing more patients access to tailored solutions across our national network."
This expansion comes at a time when consumer interest in minimally invasive body contouring is surging, particularly due to the rise in popularity of GLP-1 medications and evolving aesthetic ideals. As patients increasingly seek personalized solutions, AirSculpt recognizes the necessity to expand their portfolio of offerings to remain relevant in a competitive market.
Caro Van Hove, the President of Tiger Aesthetics, noted, "The growing demand for regenerative treatments amid the rising use of weight loss medications makes alloClae™ a compelling, non-surgical solution for patients. This partnership harnesses an innovative approach that broadens patient access nationwide while providing AirSculpt the capability to assist individuals who might otherwise have limited options."
The introduction of alloClae™ is anticipated to further enhance AirSculpt's body contouring services, enabling practitioners to tackle various aesthetic goals. This structural adipose tissue allograft adheres to the growing trend of naturalistic results, designed to add subtle volume that restores balance, smooth contours, and heightens an individual's natural silhouette. Typically performed in a convenient office setting, the procedure lasts under an hour, promising swift results coupled with minimal recovery time.
Looking ahead, AirSculpt is set to announce additional treatment options and expanded clinic availability throughout 2026 as part of its ongoing commitment to deliver personalized solutions tailored to patient needs. With the introduction of alloClae™, AirSculpt reaffirms its position as a leader in the body contouring landscape, combining cutting-edge technology with patient-centered care to achieve optimal outcomes.
AirSculpt® is recognized as a next-generation body contouring technique prioritizing patient comfort and precision. The exclusive procedures available at AirSculpt offices involve fat removal, skin tightening, and volume enhancement through fat transfer, all contributing to the sculpting of targeted body areas. Known for its quick recovery protocols, the AirSculpt process minimizes bruising and maximizes lasting results, setting a new standard in aesthetic medicine.
Slated for launch this August, alloClae™ represents AirSculpt's commitment to making innovative treatments more accessible across its network of practices. While the specifics of the locations for initial offerings remain under wraps, we can expect this exciting development to roll out to various AirSculpt locations by the end of 2026.
AlloClae™ stands out as an advantageous treatment option for individuals seeking natural-looking volume restoration without the need for a traditional fat transfer procedure. Many patients might face challenges, particularly if they do not possess sufficient fat for such procedures. This new treatment can be seamlessly integrated into existing treatment plans, allowing for enhancements in multiple areas like the hips, buttocks, and breasts, as well as smoothing out irregularities resulting from previous liposuction.
Yogi Jashnani, the Chief Executive Officer of AirSculpt, expressed the company's dedication to ongoing innovation, stating, "At AirSculpt, we are continually evaluating new technologies that complement our expertise. Our partnership with Tiger Aesthetics reflects our commitment to remaining at the forefront of body contouring innovation, allowing more patients access to tailored solutions across our national network."
This expansion comes at a time when consumer interest in minimally invasive body contouring is surging, particularly due to the rise in popularity of GLP-1 medications and evolving aesthetic ideals. As patients increasingly seek personalized solutions, AirSculpt recognizes the necessity to expand their portfolio of offerings to remain relevant in a competitive market.
Caro Van Hove, the President of Tiger Aesthetics, noted, "The growing demand for regenerative treatments amid the rising use of weight loss medications makes alloClae™ a compelling, non-surgical solution for patients. This partnership harnesses an innovative approach that broadens patient access nationwide while providing AirSculpt the capability to assist individuals who might otherwise have limited options."
The introduction of alloClae™ is anticipated to further enhance AirSculpt's body contouring services, enabling practitioners to tackle various aesthetic goals. This structural adipose tissue allograft adheres to the growing trend of naturalistic results, designed to add subtle volume that restores balance, smooth contours, and heightens an individual's natural silhouette. Typically performed in a convenient office setting, the procedure lasts under an hour, promising swift results coupled with minimal recovery time.
Looking ahead, AirSculpt is set to announce additional treatment options and expanded clinic availability throughout 2026 as part of its ongoing commitment to deliver personalized solutions tailored to patient needs. With the introduction of alloClae™, AirSculpt reaffirms its position as a leader in the body contouring landscape, combining cutting-edge technology with patient-centered care to achieve optimal outcomes.
Background on AirSculpt®
AirSculpt® is recognized as a next-generation body contouring technique prioritizing patient comfort and precision. The exclusive procedures available at AirSculpt offices involve fat removal, skin tightening, and volume enhancement through fat transfer, all contributing to the sculpting of targeted body areas. Known for its quick recovery protocols, the AirSculpt process minimizes bruising and maximizes lasting results, setting a new standard in aesthetic medicine.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.